Deciding which R&D initiatives to continue, review, or close usually means going through each one's health status, budget variance, and schedule by hand. That process can miss initiatives that have quietly stalled with no spend against them.
Hand the first pass to Prism. Ask it to assess the portfolio, and it reads health status, phase, end date, and budget variance on each initiative, then sorts each into continue, re-assess, or stop, with the reason behind each call stated directly.
Required inputs
Priority actions: two Re-assess initiatives are flagged for immediate escalation over cost overruns. Roughly 15 of the Stop initiatives show zero spend against an expired deadline and are recommended for formal closure to free governance capacity.